➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for NBI-98854

Email this page to a colleague

« Back to Dashboard

What is the drug development status for NBI-98854?

NBI-98854 is an investigational drug.

There have been 42 clinical trials for NBI-98854. The most recent clinical trial was a Phase 3 trial, which was initiated on September 14th 2018.

The most common disease conditions in clinical trials are Syndrome, Dyskinesias, and Tourette Syndrome. The leading clinical trial sponsors are Neurocrine Biosciences, AbbVie (prior sponsor, Abbott), and Huntington Study Group.

There are thirty US patents protecting this investigational drug and two hundred international patents.

Recent Clinical Trials for NBI-98854
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)Neurocrine BiosciencesPhase 2
Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential TremorNeurocrine BiosciencesPhase 2
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)Neurocrine BiosciencesPhase 3

See all NBI-98854 clinical trials

Clinical Trial Summary for NBI-98854

Top disease conditions for NBI-98854
Top clinical trial sponsors for NBI-98854

See all NBI-98854 clinical trials

US Patents for NBI-98854

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
NBI-98854   Get Started Free Valbenazine salts and polymorphs thereof Neurocrine Biosciences, Inc. (San Diego, CA)   Get Started Free
NBI-98854   Get Started Free Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyr- ido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Neuroscrine Biosciences, Inc. (San Diego, CA)   Get Started Free
NBI-98854   Get Started Free Pharmaceutical formulations Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Get Started Free
NBI-98854   Get Started Free Pharmaceutical compositions ADEPTIO PHARMACEUTICALS LIMITED (London, GB)   Get Started Free
NBI-98854   Get Started Free Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse University of Kentucky Research Foundation (Lexington, KY)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for NBI-98854

Drugname Country Document Number Estimated Expiration Related US Patent
NBI-98854 Australia AU2016343633 2035-10-30   Get Started Free
NBI-98854 Brazil BR112018008460 2035-10-30   Get Started Free
NBI-98854 Canada CA3002074 2035-10-30   Get Started Free
NBI-98854 Chile CL2018001089 2035-10-30   Get Started Free
NBI-98854 China CN108473489 2035-10-30   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.